-- Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 -- -- Combination trial of TNG462 + Revolution Medicines RAS(ON) inhibitors on track for enrollment 2Q 2025 -- -- Cash ...
– Cash position of $217 million as of March 31, 2025; cash runway extended into 1Q 2027 with reduction of preclinical spend – BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback